Alexion

AZ
Biotech

AstraZeneca posts phase 3 bone disease data on Strensiq heir

AstraZeneca shared the data behind previously disclosed phase 3 wins, fleshing out the case for an asset tipped to generate blockbuster sales.
Nick Paul Taylor Jun 29, 2026 4:51am
positive negative up down good bad mixed

AstraZeneca’s Strensiq successor misses ph. 3 rare disease goal

Mar 31, 2026 5:35am
Graphic image of an arrow nailing the bullseye of a target

AstraZeneca's blockbuster contender hits phase 3 gMG goals

Jul 24, 2025 6:20am
Goal disorientation and lack of vision

AstraZeneca amyloidosis drug fails to reduce mortality in ph. 3

Jul 16, 2025 4:28am
money scales
Favicon Fierce Pharma

Syntimmune shareholders win again over AZ, this time for $181M

Jun 12, 2025 11:40am
pivot change turnaround direction walk away

AstraZeneca CEO defends 'fantastic' Alexion buy as halts drug

Feb 6, 2025 6:45am